Skip to main content
Equibles
PYXS logo

PYXS · Pyxis Oncology, Inc.

Track PYXS — free

Use PYXS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.73 -0.02 (-0.53%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$286.92M
Shares
83.41M

PYXS metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.75
Market cap
$286.92M

Price action

19 metrics
Price change (1W)
+12.4%
Price change (30D)
+13.2%
Price change (3M)
+101.2%
Price change (6M)
+140.6%
Price change (YTD)
+199.1%
Price change (1Y)
+168.8%
Trailing year
Price change (5Y)
—
52-week high
$5.34
52-week low
$1.06
Change from 52-week high
-35.6%
Change from 52-week low
+224.5%
Annualized volatility
130.2%
Beta
1.3
RSI (14D)
58.6
Price vs SMA 50
+20.0%
Price vs SMA 200
+50.5%
Avg volume (3M)
1.17M
Relative volume
0.5
Average dollar volume
$3.28M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
83.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
101.7×
reciprocal yield 1.0%
P / book
25.1
reciprocal yield 4.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-30.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-20

Profitability

9 metrics
Gross margin
82.8%
Operating margin
-609.2%
Trailing 12 months
Net margin
-574.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$92.11M
Net income (TTM)
−$88.73M
Trailing 12 months
Diluted EPS (TTM)
$-1.40
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-12.13

Growth

11 metrics
Revenue growth YoY
-14.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.82M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-775.6%
Return on assets
-161.6%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
−$87.92M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$33.00M
Latest balance sheet
Cash & equivalents
$18.86M
Total assets
$54.92M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$67.91M
Capital expenditures (TTM)
$237,000
R&D (TTM)
$75.56M
SG&A (TTM)
—
Stock compensation (TTM)
$11.89M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
79
13F filer change QoQ
+1
Institutional ownership
41.6%

Short interest

3 metrics
Short interest
5.3%
Latest settlement · 2.0 days to cover
Days to cover
2.0d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$107,100
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1782223 CUSIP 747324101 13F (30d) 71 filings 69 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)